科興製藥(688136.SH):簽署英夫利西單抗(類停)中國大陸市場獨家推廣服務協議
格隆匯3月31日丨科興製藥(688136.SH)公佈,公司於2022年3月30日與泰州邁博太科藥業有限公司(“邁博太科”)簽署《英夫利西單抗(類停)中國大陸市場獨家推廣服務協議》,授予公司就英夫利西單抗(類停)(“標的藥品”)在中華人民共和國大陸地區(“合作區域”)獨家推廣權益。
科興製藥將支付邁博太科獨家推廣許可費1.5億元,其中首付款5000萬元;科興製藥亦將根據標的藥品在合作區域內累計銷售收入支付邁博太科商業化里程碑款。邁博太科根據協議約定向科興製藥支付推廣服務費。
標的藥品為注射用英夫利西單抗(商品名:類停),已於2021年7月獲國家藥監局批准上市(批准文號:國藥準字S20210025),是國內首個上市的英夫利西單抗生物類似藥。主要用於類風濕關節炎、銀屑病、強直性脊柱炎、成人潰瘍性結腸炎、成人及兒童克羅恩病及瘻管性克羅恩病的治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.